Navigation Links
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Lannett Company, Inc.
Date:9/4/2014

WAYNE, Pa., Sept. 4, 2014 /PRNewswire-USNewswire/ -- Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in United States District Court for the Eastern District of Pennsylvania on behalf of investors who acquired Lannett Company, Inc. ("Lannett" or the "Company") (NYSE: LCI) securities during the period from September 10, 2013 through July 16, 2014 (the "Class Period").

Lannett shareholders may, no later than October 27, 2014, move the Court for appointment as a lead plaintiff of the Class.  If you purchased shares of Lannett and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/lci.  You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com

Lannett develops, manufactures, markets and distributes generic versions of brand pharmaceutical products.  The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company's business, operations and prospects.  Specifically, the Complaint alleges that the defendants concealed from the investing public that: (1) the Company was fixing, maintaining, and controlling prices of digoxin, a drug used to treat congestive heart failure, in violation of Connecticut antitrust laws; (2) the Company was allocating and dividing customers and territories with competitors relating to the sale of digoxin in violation of Connecticut antitrust laws; (3) the Company's anticompetitive practices subjected Lannett to heightened regulatory scrutiny, including possible investigation by the Connecticut Office of the Attorney General ("CTAG"); and (4) as a result of the foregoing, Lannett's public statements were materially false and misleading at all relevant times.  As a result of defendants' alleged false and misleading statements, the Company's stock traded at artificially inflated prices during the Class Period.

According to the Complaint, on July 16, 2014, the Company issued a press release and filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that the Company received interrogatories and a subpoena from the CTAG concerning its investigation into pricing and customer/territorial division of digoxin.

On this news, shares in Lannett plummeted more than 17%, closing at $39.04 per share on July 16, 2014, on unusually heavy trading volume.

If you are a member of the class, you may, no later than October 27, 2014, request that the Court appoint you as lead plaintiff of the class.  A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Under certain circumstances, one or more class members may together serve as "lead plaintiff."  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff.  You may retain Ryan & Maniskas, LLP or other counsel of your choice, to serve as your counsel in this action.

Ryan & Maniskas, LLP is a national shareholder litigation firm.  Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

CONTACT: Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old Eagle School Rd., Suite 311
Wayne, PA 19087
877-316-3218
rmaniskas@rmclasslaw.com
www.rmclasslaw.com/cases/keg 

Logo - http://photos.prnewswire.com/prnh/20121112/MM11729LOGO


'/>"/>
SOURCE Ryan & Maniskas, LLP
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. OSE Pharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
2. Whistleblower Attorneys Sanford Heisler Announce Settlement By Smith & Nephew In Qui Tam Case
3. Pharma And Biotech Industry Veteran Selected Northwest U.S. Vice President & General Manager For Global Life Science Consulting Firm, Maetrics
4. Johnson & Johnson Responds to Ebola Crisis With Commitment to Accelerate Vaccine Program in Collaboration With the US National Institutes of Health (NIH) and Provide Humanitarian Relief Aid
5. Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare Conference
6. Cambrex To Present At Rodman & Renshaw 16th Annual Global Investment Conference
7. CytoSorbents to Present at the 2014 Rodman & Renshaw Annual Global Investment Conference
8. Frost & Sullivan Honors Clinical Ink for Developing an eSource Platform that Streamlines Clinical Development
9. RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
10. Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
11. Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2020)... ... June 23, 2020 , ... Construction at the ... now features a greatly enlarged and enhanced medical facility. Penetron crystalline technology ... tanks, and rooftop garden. , Part of the Bangkok Chain Hospital (BCH) network ...
(Date:6/19/2020)... ... June 19, 2020 , ... The Covid-19 pandemic has had ... Establishing a safe environment and compliant workforce is critical in the post-Covid world. , ... its popular SupplyBay vending machine below cost for a limited time only. , ...
(Date:6/19/2020)... NEW YORK (PRWEB) , ... ... ... announces the launch of its cross-platform campaign 'Clinical Trials.' This campaign showcases ... who participate in these studies, thereby advancing knowledge and disease treatment. This ...
Breaking Medicine Technology:
(Date:7/1/2020)... Texas (PRWEB) , ... July 01, 2020 , ... ... announced today that it has been selected by Codiak BioSciences to support its ... PODs will provide the cleanroom infrastructure for the drug substance and product manufacturing ...
(Date:6/28/2020)... ... June 26, 2020 , ... ... and the general public. As a supplier of top-quality masks, sanitizers and thermometers, ... for PPE equipment. President Priya Agarwal observed, “All of our masks are manufactured ...
(Date:6/25/2020)... ... June 25, 2020 , ... Denials Management, Inc. has ... the key steps when filing appeals for denials of mental health and substance use ... educate individuals about their appeal rights and explain the steps in the appeals process. ...
(Date:6/24/2020)... ... June 24, 2020 , ... The world’s largest cell phone trade-in price comparison ... cell phones will be worth the most two years after purchase. , The ... Samsung, Google, Sony and LG - and compared their 2018 MSRP with their trade ...
(Date:6/23/2020)... Columbia (PRWEB) , ... June 23, 2020 , ... ... Dr. Mike Hart has been named as the President of North America’s ... experience in plant based therapy, including owning and operating his own family medicine clinic ...
Breaking Medicine News(10 mins):